New York State Attorney General's Office subpoenas "documents related to Amgen's promotional activities, sales and marketing activities, medical education, clinical studies, pricing and contracting, license and distribution agreements and corporate communications," company discloses in a May 22 SEC filing. It is unclear whether the documents are related to a specific product, although the likely suspects are erythropoiesis-stimulating agentsAranesp (darbepoetin alfa) and Epogen (epoetin alfa). The firm also recently has come under scrutiny from Sen. Charles Grassley, R-Iowa, who is looking into Amgen's marketing practices for its EPO products, and how well it is providing drug safety information to FDA...

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

We clean out your Martin Luther King Day inbox so you don't have to.